首页> 外文期刊>Blood: The Journal of the American Society of Hematology >TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia
【24h】

TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia

机译:在急性早幼粒细胞白血病的变型t(3; 17)(q26; q21)易位中,TBLR1与类维生素A受体α融合

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The majority of acute promyelocytic leukemia (APL) cases are characterized by the PML-RARα fusion gene. Although the PML-RARa fusion gene can be detected in >98% of APL cases, RARα is also found to be fused with other partner genes, which are also related to all-trans retinoic acid (ATRA)-dependent transcriptional activity and cell differentiation. In this study, we identified a novel RARα fusion gene, TBLR1-RARα (GenBank KF589333), in a rare case of APL with a t(3;17)(q26;q21),t(7;17)(q11.2;q21) complex chromosomal rearrangement. To our knowledge, TBLR1-RARα is the 10th RARα chimeric gene that has been reported up to now. TBLR1-RARα contained the B-F domains of RARα and exhibited a distinct subcellular localization. It could form homodimers and also heterodimers with retinoid X receptor α. As a result, TBLR1-RARα exhibited diminished transcriptional activity by recruitment of more transcriptional corepressors compared with RARα. In the presence of pharmacologic doses of ATRA, TBLR1-RARα could be degraded, and its homo dimerization was abrogated. Moreover, when treated with ATRA, TBLR1-RARα could mediate the dissociation and degradation of transcriptional corepressors, consequent transactivation of RARα target genes, and cell differentiation induction in a dose- and time-dependent manner.
机译:多数急性早幼粒细胞白血病(APL)病例的特征是PML-RARα融合基因。尽管可以在超过98%的APL病例中检测到PML-RARa融合基因,但也发现RARα与其他伴侣基因融合,这也与全反式维甲酸(ATRA)依赖的转录活性和细胞分化有关。在这项研究中,我们确定了一种新的RARα融合基因TBLR1-RARα(GenBank KF589333),在APL罕见的情况下,其at(3; 17)(q26; q21),t(7; 17)(q11.2; q21)复杂的染色体重排。据我们所知,TBLR1-RARα是迄今为止已报道的第十个RARα嵌合基因。 TBLR1-RARα包含RARα的B-F结构域,并表现出独特的亚细胞定位。它可以与类视黄醇X受体α形成同二聚体,也可以形成异二聚体。结果,与RARα相比,TBLR1-RARα通过募集更多的转录共表达因子而表现出降低的转录活性。在存在ATRA药理剂量的情况下,TBLR1-RARα可以降解,并且其同二聚化被废止。此外,当用ATRA处理时,TBLR1-RARα可以介导剂量和时间依赖性的介导转录共加压因子的解离和降解,RARα靶基因的随后反式激活以及细胞分化诱导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号